Day: May 23, 2023

Societe Generale_ Combined General Meeting and Board of Directors dated 23 May 2023: Appointment of Slawomir Krupa, Chief Executive Officer

Societe Generale_ Combined General Meeting and Board of Directors dated 23 May 2023: Appointment of Slawomir Krupa, Chief Executive Officer

COMBINED GENERAL MEETING AND BOARD OF DIRECTORS DATED 23 MAY 2023APPOINTMENT OF SLAWOMIR KRUPA, CHIEF EXECUTIVE OFFICER Press release Paris, 23 May 2023 Combined General Meeting The General Meeting of shareholders of Societe Generale was held on 23 May 2023 at Maison de la Mutualité – 24 rue Saint-Victor – 75005 Paris and was chaired by Mr. Lorenzo Bini Smaghi. Quorum was established at 53. 45% (vs 54.83% in 2022): 681 shareholders participated by attending the General Meeting in person at the place where it was held on 23 May 2023; 914 shareholders were represented at the General Meeting on the day it was held by a person other than the Chairman; 11605 shareholders voted online; 2 754 shareholders voted by post; 9 839 shareholders, including 7 244 online, representing 1.01% of the share capital, gave proxy to the Chairman; A...

Continue reading

Safely Aware: Industry-Leading V2X Activation Equips 1.8 Million Stellantis Vehicles with Emergency Vehicle Alert System

Safely Aware: Industry-Leading V2X Activation Equips 1.8 Million Stellantis Vehicles with Emergency Vehicle Alert System

Safely Aware: Industry-Leading V2X Activation Equips 1.8 Million Stellantis Vehicles with Emergency Vehicle Alert System Stellantis’ Emergency Vehicle Alert System (EVAS) uses Uconnect connected vehicle platform system to alert drivers when emergency vehicles and other roadway hazards are nearby Breakthrough technology that enhances vehicle safety globally is a key element of the Stellantis Dare Forward 2030 strategic plan with the aim to become number one in customer satisfaction for products and service EVAS is a standard feature of Uconnect and already active on 1.8 million Chrysler, Dodge, Ram and Jeep® brand vehicles from the 2018 model year and newer in the United States and Canada EVAS works via an integration with Safety Cloud®, the nation’s largest vehicle-to-everything (V2X) platform for digital alerting from HAAS Alert Potential...

Continue reading

Totalbanken A/S og Sparekassen Danmark ønsker at fusionere

Totalbanken A/S og Sparekassen Danmark ønsker at fusionere

Bestyrelserne i Totalbanken A/S og Sparekassen Danmark har dags dato indgået en aftale om at søge en fusion mellem de to pengeinstitutter med Sparekassen som det fortsættende pengeinstitut og under navnet Sparekassen Danmark. Hensigten med fusionen er at skabe et større og stærkere pengeinstitut, og samtidig give Sparekassen Danmark et godt udgangspunkt for ekspansion på Fyn. Det fusionerede pengeinstitut vil få ca. 330.000 kunder, ca. 90.000 garanter samt ca. 1.325 medarbejdere. Instituttet vil have en balance på ca. 65 mia. kroner. Det fusionerede pengeinstitut vil have over 60 kundevendte afdelinger heraf 4 på Fyn. Der vil ikke blive afskediget medarbejdere som følge af fusionen. De fire største aktionærer i Totalbanken ejer tilsammen 57,5 % af aktierne i Totalbanken, og de har alle afgivet forhåndstilsagn om at ville stemme for fusionen. Aktionærerne...

Continue reading

PenderFund Capital Management Ltd. announces securityholder approval for fund mergers

PenderFund Capital Management Ltd. announces securityholder approval for fund mergers

VANCOUVER, British Columbia, May 23, 2023 (GLOBE NEWSWIRE) — PenderFund Capital Management Ltd. (“Pender”), the Manager of Pender Enhanced Income Fund, Pender Strategic Growth and Income Fund, Pender Value Fund, and Pender Global Focused Fund (collectively, the “Funds” and each a “Fund”), announces that it has received securityholder approval at the special meetings of the securityholders held on May 23, 2023, for the following mutual funds (each a “Terminating Fund”) to be merged into the corresponding mutual fund (each a “Continuing Fund”) (the “Mergers”), as follows: Terminating Funds Continuing Funds Pender Strategic Growth and Income Fund Pender Enhanced Income Fund Pender Global Focused Fund Pender Value Fund The Mergers are expected to take effect on or about June 23, 2023. Following the Mergers, additional changes...

Continue reading

<div>H&R Block Recognized as a Forbes Best Employer for New Graduates</div>

H&R Block Recognized as a Forbes Best Employer for New Graduates

The is the company’s fifth time being named to this list for diversity, wages, and more KANSAS CITY, Mo., May 23, 2023 (GLOBE NEWSWIRE) — Forbes today announced that H&R Block (NYSE: HRB) is a Best Employer for New Graduates. Companies were evaluated by their own young professionals on areas such as image, diversity, atmosphere, and development opportunities, and this is H&R Block’s fifth time making the list. “We value the diverse perspectives of new graduates who are not only new associations at H&R Block helping shape our Connected Culture, but also represent a growing number of our clients,” said Tiffany Monroe, Chief People & Culture Officer at H&R Block. “As our transformation journey continues, it’s a great time to be at Block. We are honored to be recognized for our efforts to be a top workplace,...

Continue reading

Phase 2 Data from “ASTRAEUS” Trial of Mereo BioPharma’s Alvelestat in Alpha-1 Antitrypsin Deficiency-associated Lung Disease Presented at the 2023 American Thoracic Society International Conference

Phase 2 Data from “ASTRAEUS” Trial of Mereo BioPharma’s Alvelestat in Alpha-1 Antitrypsin Deficiency-associated Lung Disease Presented at the 2023 American Thoracic Society International Conference

LONDON, May 23, 2023 (GLOBE NEWSWIRE) — Mereo BioPharma Group plc (NASDAQ: MREO), (“Mereo” or “the Company”), a clinical-stage biopharmaceutical company focused on rare diseases today announced that data from the Phase 2 “ASTRAEUS” trial of alvelestat for the treatment of Alpha-1 Antitrypsin Deficiency-associated Lung Disease (AATD-LD), as well as post-hoc analyses demonstrating the association between biomarker reductions with alvelestat and improvements in SGRQ, a key Patient-Reported Outcome (PRO) measure, were presented for the first time to the scientific community at the 2023 American Thoracic Society International Conference. The ASTRAEUS data were presented during an oral abstract session on novel treatments and targets by Prof. Robert Stockley, Lung Investigation Unit, University of Birmingham (United Kingdom) and Chief...

Continue reading

Microbot Medical Announces Closing of $1.4 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules

Microbot Medical Announces Closing of $1.4 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules

HINGHAM, Mass., May 23, 2023 (GLOBE NEWSWIRE) — Microbot Medical Inc. (Nasdaq: MBOT) today announced that it has closed its previously announced registered direct offering for the purchase and sale of 655,569 shares of the Company’s common stock at a purchase price of $2.20 per share of common stock priced at-the-market under Nasdaq rules. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering. The gross proceeds to the Company from the offering were approximately $1,442,252, before deducting the placement agent’s fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from the offering for the continued development, commercialization and regulatory activities for the Company’s LIBERTY® Robotic System, expansion and development of additional applications...

Continue reading

Ayala Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Corporate Update

Ayala Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Corporate Update

REHOVOT, Israel and MONMOUTH JUNCTION, N.J., May 23, 2023 (GLOBE NEWSWIRE) — Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced first-quarter 2023 financial results and provided a corporate update. “Our immediate priority is to complete enrollment in our ongoing Phase 3 registration-enabling RINGSIDE study in which we are currently evaluating AL102 in desmoid tumors,” said Ken Berlin, President and Chief Executive Officer of the Company. “We also look forward to providing a detailed update from the patients who were enrolled in Phase 2 (Part A) of RINGSIDE at the forthcoming ASCO annual meeting. For AL101, we expect to gain clarity this year on the development path in recurrent/metastatic adenoid cystic carcinoma (R/M ACC).”   First Quarter 2023 and Recent Business Highlights Completed...

Continue reading

Nova LifeStyle, Inc. Completes 1 for 5 Reverse Stock Split

Nova LifeStyle, Inc. Completes 1 for 5 Reverse Stock Split

LOS ANGELES, May 23, 2023 (GLOBE NEWSWIRE) — Nova LifeStyle, Inc. (NASDAQ: NVFY) (“Nova LifeStyle” or the “Company”) today announced that it has completed a one-for-five reverse stock split (the “Reverse Stock Split”). On May 22, 2023, the Company filed a Certificate of Change Pursuant to NRS 78.209 with the Nevada Secretary of State to effect the Reverse Stock Split, which became effective upon filing. As a result of the Reverse Stock Split, every 5 shares of the Company’s common stock issued and outstanding immediately prior to the filing of the Certificate of Change was consolidated into one issued and outstanding share. All stockholders who would be entitled to receive fractional shares as a result of the Reverse Stock Split received one whole share for their fractional share interest. There was no change in the par value of...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.